San Anselmo, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)The Ketamine Research Foundation, founded in 2017, is a small nonprofit in the Mental Health sector that reported $674K in total revenue in fiscal year 2024. Revenue fell 24% from the prior year — a significant decline worth monitoring. Expenses of $641K left a modest 5% surplus.
The specific purpose of the corporation shall include, without limitation: to evolve and provide research, training, and education in the development of Ketamine's use for psychiatric and psychotheraputic science and clinical practice.
Ketamine is the only legally available medicine with psychedelic therapeutic methodologies and practices that will serve as a model and development ground as other psychoactive medicines become...
Ketamine is the only legally available medicine with psychedelic therapeutic methodologies and practices that will serve as a model and development ground as other psychoactive medicines become available for clinical practice. This makes for streamlined and creative research, with appropriate safeguards with FDA and IRB approvals as appropriate.KRF's 2024 achievements were as follows: Completed Phantom Limb Protocol and submitted it to FDAin Review. IRB gave conditional approval based on FDA review Our Acute Trauma PTSD protocol was sent, taught and utilized in the Ukraine, Israel, North Carolina's disaster and elsewhere. KRF took leadership in dealing with trauma treatment worldwide and presented its protocol and is providing ongoing training KRF's protocol for Women's Wellbeing with the treatment of luteal face PMS and PMDD was submitted to FDA for an INDin review Setting Standards for Safe and Effective Ketamine Use-- KRF as the standard bearer for the use of ketamine clinicallyAnd for its safe use personally. KRF published major articles on KAP in academic journals, participated in numerous podcasts and programs, and had several journalistic pieces published.
KRF's Ketamine Training Center continued its practitioner training programs with over 1000 persons trained as of 2024. Our 2nd Annual Dharma K program was held as well as our Advanced Sharing...
KRF's Ketamine Training Center continued its practitioner training programs with over 1000 persons trained as of 2024. Our 2nd Annual Dharma K program was held as well as our Advanced Sharing program. WE remain as the principle and most complete training organization for KAP and Ketamine work. The BIPOC program continues to support diversity with scholarship assistance to trainees.KRF's Ketamine Psychotherapy Associates membership program now has over 100 members and provides ongoing support for practitioners and KAP practices. Our Access to Care program provide funds for our members to support those who cannot afford care.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $674,218 | $884,311 | -0.2% |
| Expenses | $641,403 | $958,705 | -0.3% |
| Net Income | $32,815 | $-74,394 | -1.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Monica Winsor | Chair of the Board | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| Ray Foote | Treasurer | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Daniel Schwartz | Secretary | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Michael Thatcher | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Bruce Richman | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Ethan Ruby | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Philip E Wolfson MD | CEO | 20.00 |
Officer
|
$136,500 | $0 | $136,500 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $674,218 | $641,403 | $560,755 | $32,815 |
| 2023 | $884,311 | $958,705 | $527,941 | $-74,394 |
| 2022 | $888,575 | $940,075 | $609,263 | $-51,500 |
| 2022 | $888,575 | $940,075 | $609,263 | $-51,500 |
| 2021 | $1,007,451 | $758,909 | $651,871 | $248,542 |
| 2020 | $428,765 | $303,687 | $403,379 | $125,078 |
| 2019 | $776,889 | $554,228 | $278,301 | $222,661 |
Compare The Ketamine Research Foundation with other nonprofits in California and across the country.